The Patent Finder
AP

Alexion Pharmaceuticals, Inc.

Filings on record here from 2001, where this site's data begins
OverviewNotableFeesChangesFamiliesPatent listSources & methods

168 patents currently held

26 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Jan 2027. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
41
Ending by 2030
Jan 2027
Next term end
101
Patent families

When these terms end

Held patents by the year their term ends
notable patents fee due within 90 days all others Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Dec 23, 2026
    The maintenance fee for Antidotes for Factor Xa Inhibitors and Methods of Using the Same (US 9,062,298) comes due Dec 23, 2026. Unpaid by Jun 23, 2027, it lapses early.
  • 2 fees due Jan 14 to 21, 2027 · next Jan 14
  • 4 fees due Feb 1 to 18, 2027 · next Feb 1
  • 4 fees due Mar 10 to 22, 2027 · next Mar 10
  • 3 fees due Apr 22 to 30, 2027 · next Apr 22
  • 3 fees due May 7 to 28, 2027 · next May 7
  • 4 fees due Jun 8 to 29, 2027 · next Jun 8
  • 2 fees due Jul 14 to 28, 2027 · next Jul 14
  • 3 fees due Aug 23 to 27, 2027 · next Aug 23
  • 3 fees due Sep 5 to 30, 2027 · next Sep 5
  • 2 fees due Oct 12 to 23, 2027 · next Oct 12

Which patents, and when each one lapses · Pro

Recent changes

  • 1 term has ended since Aug 20, 2026

What they patent

The 5 largest of its 101 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.
PatentTitleStatusExpiresConfidence
US 9,000,133Antibodies to OX-2/CD200 and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 9,718,880Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients by an Inhibitor of Complement
In force
 · Medium confidence
In forceMedium confidence
US 9,725,504Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients by an Inhibitor of Complement
In force
 · Medium confidence
In forceMedium confidence
US 9,732,149Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients by an Inhibitor of Complement
In force
 · Medium confidence
In forceMedium confidence
US 10,703,809Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients by an Inhibitor of Complement
In force
 · Medium confidence
In forceMedium confidence
US 8,709,415Antibodies to OX-2/CD200 and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 7,851,505Thiotungstate Analogues and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 10,590,189Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients by an Inhibitor of Complement
In force
 · Medium confidence
In forceMedium confidence
US 8,075,884Antibodies to OX-2/CD200 and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 9,096,677Humaneered Anti-Factor B Antibody
In force
 · High confidence
In forceHigh confidence
10 of 168 patents shown.
Pro members see all 168.
Pro members: see all 168 patents
Also on record, not counted in the 168: 26 patents in force now held by others · 86 patents ended · 89 applications pending · 240 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited